Partnering opportunity

Myocardial patch technology for cardiac regeneration

Summary

Two Italian Universities have jointly developed and patented a new technology consisting of a polymeric scaffold capable of mediating cardiac regeneration and protecting from reperfusion injury using cardioprotective agents that can be loaded on the biomatrix. They are looking for technical cooperation agreement with a company to develop the patch further in order to bring it to the market, in addition to an organization for pre-clinical validation model. Investors are also sought.

Partner sought

The universities are looking for companies that can give technical and logistic support in the production and commercialization of the myocardial patch on an industrial scale. These companies could be biomedical and pharmaceutical industries interested in the production of medical devices using meso-, micro- and nanomaterials. Can also be start-ups. An organization that can conduct GLP (Good Laboratory Practice) preclinical validation in the large animal model is also sought. Moreover, investors are sought for financial agreement.

Description

The University from Northern Italy is one of the largest Italian Universities, with 27 departments, 120 buildings and over 75,000 students. It carries out scientific research and organizes courses in all disciplines, except for Engineering and Architecture. Biotechnology and medical sciences are only some of the areas in which the University excels. The other University from Central Italy is a public institution with 20 departments and over 44,000 students. It has high level research centres in the agriculture, astrophysics, computer science, engineering, medicine and veterinary medicine sectors. Two research groups from these universities collaborated on a joint research project for the innovative myocardial patch described. Cardiovascular disease (CVD) is the single largest cause of death worldwide and is commonly associated with myocardial infarction. According to the WHO, 17.9 million deaths in 2017 were attributable to CVD, an estimated 31% of all deaths worldwide. Of these deaths, 85% are due to heart attack and stroke. Every year CVD causes over 4 million deaths in Europe. Overall CVD is estimated to cost the EU economy almost €196 billion a year. Current therapy for CVD is based on drugs, coronary artery bypass graft and angioplasty procedures. However, such therapies do not restore the functionality of damaged myocardial tissue. In addition, while use of thrombolytics and balloon angioplasty to rapidly reperfuse heart tissue with oxygen has to date greatly reduced morbidity and mortality, paradoxically, about 50% of the damage to heart tissue following myocardial infarction is a result of re-oxygenation (reperfusion injury). The rationale is to fix the problem by putting two actions together. The technology developed by researchers from these Universities is an in vivo myocardial tissue engineering technology able to simultaneously provide: 1) in situ regeneration using cardiac patch implantation and activation of endogenous cells; 2) myocardium protection from reperfusion injury using cardioprotective small molecules. The in vivo approach, which this myocardial patch pursues, poses the most ambitious challenges, but is also the most attractive option for the global market. Applications: • new therapy for cardiac tissue regeneration • localized cardioprotective drug delivery system • intelligent scaffold for tissue repair after myocardial infarction • nanotechnology for in situ control of endogenous cells and stem cell niche The Universities are looking for investors as well as for companies and start-ups that can give technical and logistic support in the production and commercialization of the myocardial patch on an industrial scale. These companies could be biomedical and pharmaceutical industries interested in the production of medical devices using meso-, micro- and nanomaterials. An organization that can conduct GLP (Good Laboratory Practice) preclinical validation in the large animal model is also sought.

Advantages and innovations

The biomedical industry values the absence of an in vitro culture phase as highly advantageous for the following reasons: • use of materials independent on the individuality of each patient • immediate applicability of the device without delays due to cell culturing (the only opportunity to address the acute phase) • higher product transportability and storage as compared with cellularized scaffolds • complete feasibility within industrial facilities. Moreover, the developed cardiac patches: • Mimic myocardium structure and biomechanics • Are biocompatible • Are cardioinductive • Have a cardioprotective effect, to limit reperfusion injury • Are easily implanted in vivo (large animal model) • Are completely absorbed within 3 months

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patents granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company